A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

Prominent gaps in pediatric and adolescent HIV care translate into priorities that need to be addressed for optimizing care ...

Without urgent intervention, Kenya risks a surge in new HIV infections, which currently stand at 16,752 annually, NSDCC said.